Revelation Biosciences, Inc. (NASDAQ:REVB – Free Report) – Investment analysts at Roth Capital issued their FY2029 earnings per share estimates for shares of Revelation Biosciences in a report issued on Friday, March 7th. Roth Capital analyst J. Aschoff forecasts that the company will post earnings of $2.23 per share for the year. The consensus estimate for Revelation Biosciences’ current full-year earnings is ($49.33) per share.
Revelation Biosciences Trading Up 0.9 %
Shares of REVB opened at $3.49 on Monday. Revelation Biosciences has a twelve month low of $3.19 and a twelve month high of $60.80. The stock’s 50 day moving average is $5.44 and its two-hundred day moving average is $9.95. The firm has a market capitalization of $935,320.00, a PE ratio of -0.01 and a beta of 0.17.
About Revelation Biosciences
Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.
Read More
- Five stocks we like better than Revelation Biosciences
- Upcoming IPO Stock Lockup Period, Explained
- Institutional Investors Bet $1B on These 4 Stocks—Should You?
- What is a Dividend King?
- One Must-Buy Stock and One to Avoid as Tariffs Shake the Market
- The How and Why of Investing in Gold Stocks
- These 4 Tech ETFs Just Hit 50-Day Lows—Time to Buy?
Receive News & Ratings for Revelation Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revelation Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
